{"raw_mentions": "Here are the extracted sentences:\n\nFor the MRI imaging of thrombosis a Gadolinium dose of 30 \u03bc\u03b7\u03b7\u03bf\u0399 Gd/kg bodyweigh (7.5 \u03bc\u03b7\u03b7\u03bf\u0399 EP2104R/kg bw) t is used.\nThe detection limit of clinical available contrast agents is around 20 \u03bc\u03b7\u03b7\u03bf\u0399 Gd/L for in vitro and preclinical animal testing (Ciesienski et.al., Curr Cardiovasc Imaging Rep. 2010, 4(1 ), 77-84) and 125 \u03bc\u03b7\u03b9\u03bf\u0399 Gd/L for robust clinical application (Caravan et. al. Chem. Soc. Rev., 2006, 35, 512-523).\nThe used standard dose of established contrast agents is 100 \u03bc\u03b7\u03b7\u03bf\u0399 Gd/kg bodyweight which leads to an average plasma concentration of about 590 \u03bc\u03b7\u03b7\u03bf\u0399 Gd/L 2 min post application (summary of product characteristics: Gadovist 1.0 mmol/ml solution for injection, Fachinformation Gadovist<sup>\u00ae</sup> 1 ,0 \nThe used plasma concentration of the described compounds (0.8 \u03bc\u03b7\u03b7\u03bf\u0399 Gadolinium/L) was in the order of magnitudes lower that the approved market products.\nThe surprising effect of using extremely low doses was confirmed in an in vivo monkey experiment, (total dose: 4 \u03bc\u03b7\u03b7\u03bf\u0399 Gd/ kg bodyweight equals 0.5 \u03bc\u03b7\u03b7\u03bf\u0399 molecule/kg bw) \nThe dosage was in an at least 7.5-fold up to 25-fold lower compared to the most advanced preclinical thrombus specific imaging MRI experiments described by Klink et. al. (100 \u03bc\u03b7\u03b7\u03bf\u0399 Gd/kg"}
{"final_json": [{"molecule_name": "Gadolinium", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "30", "unit": "\u03bc\u03b7\u03b7\u03bf\u0399 Gd/kg"}, {"molecule_name": "Gadolinium", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "20", "unit": "\u03bc\u03b7\u03b7\u03bf\u0399 Gd/L"}, {"molecule_name": "Gadolinium", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "125", "unit": "\u03bc\u03b7\u03b9\u03bf\u0399 Gd/L"}, {"molecule_name": "Gadolinium", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "100", "unit": "\u03bc\u03b7\u03b7\u03bf\u0399 Gd/kg"}, {"molecule_name": "Gadolinium", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "590", "unit": "\u03bc\u03b7\u03b7\u03bf\u0399 Gd/L"}, {"molecule_name": "Gadolinium", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "0.8", "unit": "\u03bc\u03b7\u03b7\u03bf\u0399 Gadolinium/L"}, {"molecule_name": "Gadolinium", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "4", "unit": "\u03bc\u03b7\u03b7\u03bf\u0399 Gd/ kg"}, {"molecule_name": "Gadolinium", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "0.5", "unit": "\u03bc\u03b7\u03b7\u03bf\u0399 molecule/kg"}, {"molecule_name": "Gadolinium", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "100", "unit": "\u03bc\u03b7\u03b7\u03bf\u0399 Gd/kg"}]}
{"raw_mentions": "Unfortunately, there are no sentences that meet the specified criteria in the provided text snippet. The text primarily describes experimental methods and procedures, but does not include specific molecule names, bioactivity metrics with numeric values, and units. \n\nHowever, I can suggest that you may want to look into Table 1, which is mentioned in the text as summarizing the binding affinity of compounds towards human GPIIb/llla receptor. The actual table is not provided in the text snippet, but it may contain the relevant information you are looking for."}
